Xolair 150 MG/ML autoinjectorml
Ended Awarded
- Contract number
- SPE2DB25FZL01
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $6,849
Award facts
- Contract value 100% obligated
- $6,848.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $6,848.88 by the Defense Logistics Agency (DLA) on September 3, 2025. The contract calls for the delivery of Xolair 150 mg/ml auto-injector medication, with an ultimate completion date of September 24, 2025. No set-aside designation was applied to this award. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that authorizes the agency to issue firm fixed-price delivery orders for pharmaceutical products supporting military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing contracts with the DLA to distribute branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. The company's extensive portfolio of previous awards demonstrates capability across diverse product categories including specialty medications, auto-injectors, oncology treatments, and vaccines. The Xolair delivery fulfills the DLA's ongoing requirement for pharmaceutical supplies to support military medical operations and represents a continuation of the company's role as a primary distributor of specialized pharmaceutical products to federal healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FZL01?
SPE2DB25FZL01 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 3, 2025.
How much is contract SPE2DB25FZL01 worth?
The government has obligated $6,849 on SPE2DB25FZL01.
Is contract SPE2DB25FZL01 an order under another contract?
Yes. SPE2DB25FZL01 is a delivery order under SPE2DB20D9329, an indefinite delivery contract.
Was contract SPE2DB25FZL01 competed?
The extent of competition for SPE2DB25FZL01 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award